🔒 Secure Checkout
|
Free Research Guides →
Research Guide · Tesemorelin

What is Tesemorelin?

A comprehensive exploration of the GHRH analogue redefining growth hormone peptide research—its chemistry, mechanism, and clinical application profile.

Updated September 2026 Research Use Only 12 min read

What is Tesemorelin?

An introduction to tesemorelin’s identity as a stabilised growth hormone-releasing hormone analogue with distinct structural and pharmacological properties.

01

Structure & Chemistry

Tesemorelin (USAN: tesamorelin) is a synthetic 44-amino acid polypeptide analogue of human growth hormone-releasing hormone. The molecule retains the complete native GHRH 1–44 sequence whilst incorporating a trans-3-hexenoic acid modification at the N-terminus. This fatty acid conjugate provides marked resistance to degradation by dipeptidyl peptidase IV (DPP-IV), extending functional half-life from minutes to approximately 26–38 minutes. Molecular weight is approximately 5,135.9 Daltons.

02

Receptor & Signalling

Tesemorelin is a highly selective agonist at the growth hormone-releasing hormone receptor (GHRHR), a G protein-coupled receptor expressed predominantly on anterior pituitary somatotroph cells. Binding initiates adenylyl cyclase signalling, elevating intracellular cAMP and engaging protein kinase A (PKA) and mitogen-activated protein kinase (MAPK) cascades. This stimulates GH gene expression and triggers pulsatile endogenous growth hormone secretion—not exogenous replacement.

03

Clinical Approval & Status

Developed by Theratechnologies Inc., tesemorelin was approved by the United States FDA in 2010 under the brand name Egrifta for reducing excess abdominal fat in HIV-infected patients with lipodystrophy. The original Egrifta and Egrifta SV formulations have since been succeeded by Egrifta WR (tesamorelin F8), approved in March 2025, which replaces Egrifta SV and needs reconstituting weekly rather than daily. The peptide remains a subject of active research in metabolic syndrome, body composition, and ageing studies.

Mechanism of Action

How tesemorelin stimulates endogenous growth hormone release and alters metabolic physiology through distinct molecular pathways.

01
GHRHR Binding & Signal Transduction
Upon subcutaneous administration, tesemorelin circulates to the anterior pituitary and binds GHRH receptors on somatotroph cell membranes. This activates coupled heterotrimeric Gs protein, stimulating adenylyl cyclase and raising intracellular cAMP. Elevated cAMP activates protein kinase A (PKA), which phosphorylates the transcription factor CREB. CREB subsequently enhances pituitary-specific transcription factor Pit-1 expression, driving GH gene transcription and synthesis within somatotrophs (Frohman & Giustina, 2006).
02
Endogenous GH Secretion & IGF-1 Induction
Unlike exogenous recombinant human GH (rhGH) therapy, tesemorelin preserves physiological pulsatile growth hormone release. Stimulated somatotrophs secrete GH in episodic pulses, which circulate to the liver and stimulate hepatic insulin-like growth factor 1 (IGF-1) synthesis. Clinical trials demonstrated IGF-1 elevation by approximately 81% in tesemorelin cohorts versus 5% decline in placebo, confirming robust endocrine stimulation and preservation of axis feedback mechanisms (Koutkia et al., 2004).
03
Visceral Adipose Tissue Mobilisation
Elevated endogenous GH activates hormone-sensitive lipase (HSL) in visceral adipocytes through beta-adrenergic signalling, promoting triglyceride hydrolysis and lipolysis. Critically, this mobilisation is selective for visceral (deep, metabolically active) adipose tissue rather than subcutaneous fat, likely due to differential adrenergic receptor density and insulin sensitivity in visceral depots. Growth hormone also exerts direct lipolytic effects via GH receptor signalling, amplifying fatty acid oxidation and mobilisation from internal organs. The selectivity for visceral adiposity is a key distinguishing feature of tesemorelin’s mechanism, as visceral fat is strongly associated with metabolic dysfunction, hepatic insulin resistance, ectopic lipid deposition, and cardiovascular risk—hence its reduction offers meaningful clinical and research significance.
04
Metabolic & Compositional Changes
The net result is selective lipid mobilisation coupled with increased protein synthesis in muscle tissue. Major clinical data document visceral adiposity reductions of approximately 15.2% over 26 weeks versus 5% increase in placebo groups. Triglycerides decreased by 50 mg/dL in tesemorelin-treated subjects versus 9 mg/dL increase in placebo. Concurrently, skeletal muscle area increased whilst hepatic steatosis and inflammatory markers improved, reflecting a shift to a metabolically favourable body composition (Thompson et al., 2008).

Tesemorelin vs Other GH-Axis Peptides

Structural, pharmacokinetic, and mechanistic comparison of tesemorelin with sermorelin, CJC-1295, ipamorelin, and GHRP-6 in research applications.

Peptide
Classification & Mechanism
Half-Life & Dosing
Tesemorelin
GHRH analogue (44-aa); N-terminal hexenoyl stabilisation; GHRHR agonist
26–38 min; daily subcutaneous
Sermorelin
GHRH analogue (29-aa core); shorter-acting GHRHR agonist
7–15 min; daily or multiple daily dosing
CJC-1295
GHRH analogue (29-aa); available ± DAC (Drug Affinity Complex); extended half-life variant
7–8 days (with DAC); weekly or bi-weekly
Ipamorelin
GHRP pentapeptide; ghrelin receptor (GHS-R1a) agonist; non-GHRH pathway; minimal cortisol/prolactin elevation
2–3 hours; can be dosed multiple times daily
GHRP-6
GHRP hexapeptide; ghrelin receptor agonist; can elevate cortisol and prolactin; older generation
30 min–1 hour; multiple daily dosing typical

Research Context: Tesemorelin’s FDA approval for HIV lipodystrophy and established clinical safety distinguish it among GHRH analogues. Its intermediate half-life requires daily dosing but permits precise GH pulse control, a critical advantage when investigating acute or transient GH responses in experimental models. CJC-1295 offers dosing convenience (weekly) but produces sustained, non-physiological GH elevation unsuitable for studying pulsatile secretion patterns. Sermorelin suits research seeking acute, timed GH responses but has shorter half-life and reduced potency. Ipamorelin and GHRP-6 activate parallel ghrelin pathways, enabling researchers to explore multi-target GH secretion strategies independent of direct GHRH receptor engagement, making them valuable for comparative mechanistic studies. For researchers prioritising clinical relevance combined with physiological GH pattern preservation, tesemorelin remains the preferred GHRH analogue option.

Key Research Applications

Primary domains where tesemorelin has demonstrated research utility and established scientific foundations.

01
HIV-Associated Lipodystrophy & Visceral Adiposity
The foundation for tesemorelin research. Randomised controlled trials established its efficacy in reducing visceral adipose tissue volume by 15–27.8 cm² over 26 weeks, with associated improvements in triglycerides, total cholesterol-to-HDL ratio, and hepatic steatosis in antiretroviral therapy-treated patients. These findings have positioned tesemorelin as both a therapeutic agent and a research tool for understanding antiretroviral drug-induced metabolic complications and visceral fat physiology (Thompson et al., 2008; Liu et al., 2008).
02
Body Composition & Muscle-Fat Redistribution
Beyond visceral fat reduction, research has explored tesemorelin’s anabolic effects on lean muscle mass and intramuscular lipid profile. Studies document increases in skeletal muscle area and density in responders, alongside improvements in subcutaneous fat quality (increased density indicating metabolic improvement). This research informs understanding of endogenous GH stimulation in sarcopenia, metabolic syndrome, and cachexia models, offering alternatives to exogenous GH therapy. The preservation of pulsatile GH secretion patterns during tesemorelin treatment appears to drive more physiological muscle protein synthesis responses and improved fat-free mass preservation compared to continuous GH exposure, making tesemorelin particularly valuable for age-related sarcopenia research models (Falutz et al., 2010).
03
Metabolic Syndrome & Cardiometabolic Risk
Tesemorelin research has illuminated the relationship between visceral adiposity and systemic metabolic health. Reduction in VAT volume correlates with improvements in insulin sensitivity, lipid panels (reduced triglycerides, improved cholesterol ratios), and inflammatory biomarkers including C-reactive protein and interleukin-6. This research supports the hypothesis that visceral, not subcutaneous, fat drives cardiometabolic dysfunction through ectopic lipid deposition, hepatic triglyceride elevation, and endothelial dysfunction, and that targeted visceral fat reduction via endogenous GH stimulation may offer therapeutic benefit in metabolic syndrome and type 2 diabetes risk reduction. The mechanistic insight gained from tesemorelin studies has informed broader understanding of GH axis physiology in metabolic disease.
04
Neurocognitive Function & Sleep Architecture
Emerging research has examined tesemorelin’s effects on cognitive performance and sleep quality through normalised GH pulsatility and enhanced central IGF-1 signalling. Earlier studies suggested improvements in executive function and verbal memory in mild cognitive impairment cohorts; however, recent data in HIV-positive patients with abdominal obesity show more cautious conclusions, with some cognitive benefits not reaching statistical significance. Sleep architecture studies remain preliminary but indicate potential improvements in sleep consolidation and recovery quality via GH-dependent mechanisms (Leung et al., 2021).
05
Ageing & Somatopause Investigation
Research has investigated tesemorelin’s role in restoring endogenous GH secretion in older adults, where age-related decline in hypothalamic GHRH output and pituitary GHRH sensitivity contribute to frailty, muscle loss, and visceral fat accumulation. Tesemorelin can partially restore GH pulsatility in aged populations, providing a physiologically relevant model for studying consequences of GH restoration without risks of exogenous rhGH therapy. This research supports exploration of GHRH agonists as alternatives to direct GH replacement in age-related somatopause.

Quick Reference · Specifications

Essential biochemical and pharmaceutical parameters for research protocol development and implementation.

P · 01
IUPAC/USAN Name
Tesamorelin acetate (USAN: tesamorelin)
P · 02
Amino Acid Composition
44 amino acids; full human GHRH 1–44 sequence with N-terminal trans-3-hexenoyl modification
P · 03
Molecular Weight
~5,135.9 Daltons
P · 04
Half-Life (Subcutaneous)
26–38 minutes; mean ~30 min after daily dosing
P · 05
Tmax (Peak Concentration)
0.15 hours (~9 minutes post-injection)
P · 06
Bioavailability (Subcutaneous)
<4% (peptides undergo rapid hepatic and peripheral proteolysis)
P · 07
Primary Mechanism
GHRH receptor (GHRHR) agonist; endogenous pituitary GH secretion stimulation
P · 08
Receptor Selectivity
Highly selective GHRHR; minimal off-target activity on other G protein-coupled receptors
P · 09
Route of Administration (Research)
Subcutaneous injection; daily dosing typical in published studies
P · 10
Storage (Lyophilised Vial)
2–8°C (refrigerate); protect from light; long-term stability years

Reconstitution & Storage Guidance

Best practices for maintaining peptide stability and bioactivity throughout research applications.

01
Reconstitution Medium & Asepsis
Lyophilised Tesemorelin must be reconstituted with bacteriostatic water (0.9% sodium chloride with 0.9% benzyl alcohol). The benzyl alcohol preservative is essential — it inhibits bacterial and fungal growth, enabling multiple dose withdrawals from a single vial over days or weeks without microbial contamination. Reconstitution requires aseptic technique: use a sterile 3 mL or 10 mL syringe and sterile needle. Allow the powder to dissolve gently; vigorous agitation or shaking causes peptide denaturation via air-bubble formation and mechanical stress.
02
Storage Conditions & Stability Timeline
Once reconstituted with bacteriostatic water, tesemorelin solutions must be stored at 2–8°C in a standard laboratory refrigerator. Under these conditions, reconstituted solutions maintain bioactivity and stability for approximately 3–6 weeks, with some high-quality protocols extending this to 4–6 weeks depending on vial integrity and aseptic handling adherence. Solutions should be protected from direct light exposure using amber vials or aluminium foil wrapping around the vial. Freeze-thaw cycles must be strictly avoided, as repeated freezing and thawing cause peptide aggregation, particle formation, and irreversible loss of biological activity.
03
Quality Verification & Visual Inspection
Before use, reconstituted tesemorelin solutions must be visually inspected for clarity, colour, and particulates. A clear, colourless to slightly yellow solution is expected; any cloudiness, visible particles, discoloration, or precipitate indicates peptide degradation or contamination and the solution must be discarded. Sterile 0.22 μm syringe filters may be used to remove particulates if desired, although filtration of peptide solutions requires care to avoid non-specific absorption onto filter membranes.
04
Handling Best Practices & Documentation
To preserve peptide integrity throughout extended research programmes: maintain consistent refrigeration at 2–8°C; minimise air exposure by using sealed sterile syringes; avoid shaking or vigorous mixing; use fresh sterile needles for each withdrawal; never expose solutions to direct sunlight or heat; allow solutions to reach room temperature gradually before use to prevent thermal shock; document the reconstitution date and time on every vial for traceability; and discard any solution older than six weeks or showing visual signs of degradation.

Key Published Research

The clinical trials behind tesamorelin’s approval.

2007
Phase 3 (NEJM)
In adults with HIV and abdominal fat accumulation, tesamorelin reduced visceral adipose tissue compared with placebo, and improved lipid measures, without significant changes in glucose control.1
2010
Pooled phase 3 analysis
Pooled data from two multicentre phase 3 trials with safety extensions confirmed visceral-fat reduction and showed the effect reversed after treatment stopped.2
2014
Liver fat (JAMA)
In a randomised trial, tesamorelin reduced both visceral fat and liver fat in people with HIV.3
2019
NAFLD (Lancet HIV)
A randomised, double-blind multicentre trial found tesamorelin reduced liver fat and prevented fibrosis progression in HIV-associated non-alcoholic fatty liver disease.4

Regulatory & Research Status

Where tesamorelin stands in 2026.

MAR 25
Egrifta WR approved
The FDA approved Egrifta WR (tesamorelin F8), eight times more concentrated than the original formulation, with weekly rather than daily reconstitution. It replaces Egrifta SV.
NAME
Spelling
The international non-proprietary name is tesamorelin; “tesemorelin” is a common alternative spelling.
SPORT
WADA
GHRH analogues, including tesamorelin, are prohibited at all times on the 2026 WADA list.

Evidence Quality & Limitations

Tesamorelin’s evidence is strong for its approved indication — visceral fat in HIV-associated lipodystrophy — and growing for HIV-associated fatty liver disease. Evidence outside HIV is limited, and benefits in the pivotal trials reversed after treatment stopped. Because it raises IGF-1, trials monitored glucose tolerance and IGF-1 levels throughout.

References

  1. Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357:2359–70. PubMed
  2. Falutz J, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010;95:4291–304. PubMed
  3. Stanley TL, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312:380–9. PubMed
  4. Stanley TL, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019;6:e821–30. PubMed
⚠ Research Use Only. The compounds discussed in this guide are intended strictly for in-vitro laboratory research. They are not intended for human consumption, therapeutic use, or veterinary application. Researchers must comply with all applicable local regulations.
Scroll to Top
Login / Register
BioCompounds UK Shield of Scientific Integrity

Welcome back